Abstract
Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) quantifies blood–brain
barrier (BBB) microvascular permeability in brain tumors where it is structurally
and functionally abnormal. Twenty-five patients with glioblastomas (105 regions of
interest) were compared using DCE-MRI metrics obtained with Tofts–Kety (TK) and extended
TK (ETK) models using different arterial input function assessments and different
initial area under the gadolinium curve (IAUGC) indices.
Strong correlations between ve and IAUGC90 were found (EKT model: R=0.75 and R=0.69), while correlations of Ktrans with both IAUGC80/90 indices were weak. Differences in the permeability parameters, calculated by these
two models, were found.
While the IAUGC method can be implemented more easily than pharmacokinetic models,
at this time, the IAUGC approach alone does not substitute pharmacokinetic models
in BBB permeability characterization.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical ImagingAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Cerebrospinal fluid: blood–brain barrier, brain edema, and hydrocephalus.in: Principles of neural science. 3rd ed. Elsevier, New York2001: 1050-1060
- Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumors in vivo.Cancer Res. 2001; 61: 6020-6024
- Vascular permeability and microcirculation of gliomas and mammary carcinomas transplanted in rat and mouse cranial windows.Cancer Res. 1994; 54: 4564-4568
- Vessel tortuosity and brain tumor malignancy: a blinded study.Acad Radiol. 2005; 12: 1232-1240
- In situ expression of angiopoietins in astrocytomas identifies angiopoietin-2 as an early marker of tumor angiogenesis.Exp Neurol. 1999; 159: 391-400
- Microvascular abnormalities in virally-induced canine brain tumors. Structural bases for altered blood–brain barrier function.J Neurol Sci. 1972; 17: 29-39
- Vasculature of neural neoplasms.Adv Neurol. 1976; 15: 27-49
- Phase I dose-finding study of pazopanib in hepatocellular carcinoma: evaluation of early efficacy, pharmacokinetics, and pharmacodynamics.Clin Cancer Res. 2011; 17: 6914-6923
- Dynamic contrast-enhanced magnetic resonance imaging-derived kep as a potential biomarker of matrix metalloproteinase 9 expression in patients with glioblastoma multiforme: a pilot study.J Comput Assist Tomogr. 2012; 36: 125-130
- Dynamic contrast-enhanced (DCE) derived transfer coefficient (ktrans) is a surrogate marker of matrix metalloproteinase 9 (MMP-9) expression in brain tuberculomas.J Magn Reson Imaging. 2008; 28: 588-597
- Dynamic contrast-enhanced magnetic resonance imaging as a surrogate marker of tumor response to anti-angiogenic therapy in a xenograft model of glioblastoma multiforme.J Magn Reson Imaging. 2002; 15: 233-240
- Integration of quantitative DCE-MRI and ADC mapping to monitor treatment response in human breast cancer: initial results.Magn Reson Imaging. 2007; 25: 1-13
- Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols.J Magn Reson Imaging. 1999; 10: 223-232
- Modeling tracer kinetics in dynamic Gd-DTPA MR imaging.J Magn Reson Imaging. 1997; 7: 91-101
- Uncertainty in the analysis of tracer kinetics using dynamic contrast-enhanced T1-weighted MRI.Magn Reson Med. 2002; 47: 601-606
- Measurement of blood–brain barrier permeability with T1-weighted dynamic contrast-enhanced MRI in brain tumors: a comparative study with two different algorithms.ISRN Neurosci. 2013; 2013 ([6 pages])
- Temporal resolution and SNR requirements for accurate DCE-MRI data analysis using the AATH model.Magn Reson Med. 2010; 64: 1772-1780
- Measurement of brain perfusion, blood volume, and blood–brain barrier permeability, using dynamic contrast-enhanced T(1)-weighted MRI at 3 tesla.Magn Reson Med. 2009; 62: 1270-1281
- The inclusion of capillary distribution in the adiabatic tissue homogeneity model of blood flow.Phys Med Biol. 2001; 46: 1519-1538
- A comparison of tracer kinetic models for T1-weighted dynamic contrast-enhanced MRI: application in carcinoma of the cervix.Magn Reson Med. 2010; 63: 691-700
- Validity of perfusion parameters obtained using the modified Tofts model: a simulation study.Magn Reson Med. 2011; 65: 1491-1497
- Comparative study of methods for determining vascular permeability and blood volume in human gliomas.J Magn Reson Imaging. 2004; 20: 748-757
- Measurement of the blood–brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts.Magn Reson Med. 1991; 17: 357-367
- Evaluation of area under curve [Gd] data derived from DCE-MRI time series in brain tumours.Proc Int Soc Magn Reson Med. 2003; 11: 1267
- Dynamic contrast-enhanced magnetic resonance imaging in oncology.2005
- Evaluation of response to treatment using DCE-MRI: the relationship between initial area under the gadolinium curve (IAUGC) and quantitative pharmacokinetic analysis.Phys Med Biol. 2006; 51: 3593-3602
- Quantitative dynamic contrast-enhanced MRI of pelvic and lumbar bone marrow: effect of age and marrow fat content on pharmacokinetic parameter values.AJR Am J Roentgenol. 2013; 200: W297-W303
- Dynamic contrast-enhanced magnetic resonance imaging of canine brain tumors.Vet Radiol Ultrasound. 2010; 51: 122-129
- Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings.Radiology. 1994; 191: 41-51
- Quantitative measurement of leakage volume and permeability in gliomas, meningiomas and brain metastases with dynamic contrast-enhanced MRI.Magn Reson Imaging. 2005; 23: 833-841
- Differentiation of low-grade oligodendrogliomas from low-grade astrocytomas by using quantitative blood-volume measurements derived from dynamic susceptibility contrast-enhanced MR imaging.AJNR Am J Neuroradiol. 2005; 26: 266-273
- High cerebral blood volume in human gliomas predicts deletion of chromosome 1p: preliminary results of molecular studies in gliomas with elevated perfusion.J Magn Reson Imaging. 2007; 25: 1113-1119
- Comparative study into the robustness of compartmental modeling and model-free analysis in DCE-MRI studies.J Magn Reson Imaging. 2006; 23: 554-563
- Rapid combined T1 and T2 mapping using gradient recalled acquisition in the steady state.Magn Reson Med. 2003; 49: 515-526
- Gd-DTPA relaxivity depends on macromolecular content.Magn Reson Med. 2000; 44: 665-667
- Pharmacokinetics of GdDTPA/dimeglumine after intravenous injection into healthy volunteers.Physiol Chem Phys Med NMR. 1984; 16: 167-172
- Measuring permeability in acute ischemic stroke.Neuroimaging Clin N Am. 2011; 21 ([x-xi]): 315-325
- Evolution of the blood–brain barrier in newly forming multiple sclerosis lesions.Ann Neurol. 2011; 70: 22-29
- Blood–brain barrier permeability abnormalities in vascular cognitive impairment.Stroke. 2011; 42: 2158-2163
- Alterations in the blood brain barrier in ageing cerebral cortex in relationship to Alzheimer-type pathology: a study in the MRC-CFAS population neuropathology cohort.Neurosci Lett. 2011; 505: 25-30
- Reproducibility of quantitative dynamic MRI of normal human tissues.NMR Biomed. 2002; 15: 143-153
- Quantitative imaging biomarkers in the clinical development of targeted therapeutics: current and future perspectives.Lancet Oncol. 2008; 9: 766-776
- Experimentally-derived functional form for a population-averaged high-temporal-resolution arterial input function for dynamic contrast-enhanced MRI.Magn Reson Med. 2006; 56: 993-1000
- Key factors in the acquisition of contrast kinetic data for oncology.J Magn Reson Imaging. 1999; 10: 254-259
- Relationship between human tumour angiogenic profile and combretastatin-induced vascular shutdown: an exploratory study.Br J Cancer. 2008; 99: 321-326
- DCE and DW MRI in monitoring response to androgen deprivation therapy in patients with prostate cancer: a feasibility study.Magn Reson Med. 2011; 67: 778-785
- Dynamic MRI for imaging tumor microvasculature: comparison of susceptibility and relaxivity techniques in pelvic tumors.J Magn Reson Imaging. 2007; 25: 796-805
- DCE-MRI at 3 T in patients with advanced prostate cancer undergoing androgen deprivation therapy.Proc Int Soc Magn Reson Med. 2010; 18: 2801
- Vascular disrupting effect of CKD-516: preclinical study using DCE-MRI.Invest New Drugs. 2013; 31: 1097-1106
- Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters.AJR Am J Roentgenol. 2007; 189: 849-858
- Effects of platinum/taxane based chemotherapy on acute perfusion in human pelvic tumours measured by dynamic MRI.Br J Cancer. 2005; 93: 979-985
- Prostate cancer: evaluation of vascular characteristics with dynamic contrast-enhanced T1-weighted MR imaging—initial experience.Radiology. 2004; 233: 709-715
- Method for quantitative mapping of dynamic MRI contrast agent uptake in human tumors.J Magn Reson Imaging. 2001; 14: 457-463
- Improved 3D quantitative mapping of blood volume and endothelial permeability in brain tumors.J Magn Reson Imaging. 2000; 12: 347-357
Article info
Publication history
Published online: July 22, 2014
Accepted:
July 10,
2014
Received in revised form:
June 9,
2014
Received:
December 24,
2013
Identification
Copyright
© 2014 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
